Volume 13 Issue 2 2012 Article The Commercial Exploitation Continuum Philip W. Goter View Full Article In This Issue Faculty Masthead Student Masthead The Role of Law in the Debate over Return of Research Results and Incidental Findings: The Challenge of Developing Law for Translational Science Returning Individual Research Results: What Role Should People’s Preferences Play? Deidentification and Reidentification in Returning Individual Findings from Biobank and Secondary Research: Regulatory Challenges and Models for Management Incidental Findings in Genetic Research: A Vexing Challenge for Community Consent Returning Genetic Research Results: Considerations for Existing No-Return and Future Biobanks Enforcing the Rights of Human Sources to Informed Consent and Disclosures of Incidental Findings from Biobanks and Researchers: State Mechanisms in Light of Broad Regulatory Failure Perspective on Biorepository Return of Results and Incidental Findings The Informed Cohort Oversight Board: From Values to Architecture The Tension Between Policy and Practice in Returning Research Results and Incidental Findings in Genomic Biobank Research Rethinking Lohr: Does “SE” Mean Safe and Effective, Substantially Equivalent, or Both? The Commercial Exploitation Continuum Defining the Essence of Being Human It’s the Autonomy, Stupid: Political Data-Mining and Voter Privacy in the Information Age John Wiley & Sons, Inc. v. Kirtsaeng: The Uncertain Future of the First-Sale Doctrine Rethinking Off-Label Regulation in the Wake of Sorrell v. IMS Health: Can State Involvement Compensate for Waning FDA Authority to Curb Commercial Free Speech?